Department of Pharmaceutical Sciences, 521 Hochstetter Hall, University at Buffalo, The State University of New York, Amherst, New York 14260, USA.
J Pharm Sci. 2010 Jun;99(6):2557-75. doi: 10.1002/jps.22054.
The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethylene glycol) (PEG), polysialic acid, or glycolic acid, as well as developing new formulations containing nanoparticulate or colloidal systems (e.g., liposomes, polymeric microspheres, polymeric nanoparticles). Such strategies have the potential to develop as next generation protein therapeutics. This review includes a general discussion on these delivery approaches.
蛋白质治疗药物的安全性和疗效受到三个相互关联的药物问题的限制，即体外和体内不稳定性、免疫原性和半衰期较短。为克服这些问题，正在研究新型药物修饰方法，包括聚（乙二醇）（PEG）、唾液酸多糖或乙醇酸的共价连接，以及开发包含纳米颗粒或胶体系统（例如脂质体、聚合物微球、聚合物纳米颗粒）的新配方。这些策略有可能开发成为下一代蛋白质治疗药物。本文综述了这些递药方法。
